Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009 Jun 09; 119(22):2877-85.

View in: PubMed

subject areas

Acute Coronary Syndrome
Adolescent
Adult
Aged
Aged, 80 and over
Aspirin
Dose-Response Relationship, Drug
Double-Blind Method
Drug Therapy, Combination
Factor Xa Inhibitors
Female
Hemorrhage
Humans
Male
Middle Aged
Myocardial Ischemia
Platelet Aggregation Inhibitors
Pyrazoles
Pyridones
Ticlopidine
Young Adult

authors with profiles

Robert Harrington